Beruflich Dokumente
Kultur Dokumente
Steatohepataitis (NASH)”
Epidemiology
o In this section, epidemiology of NASH is reviewed to understand potential
significance and impact of the disease.
o Global & US prevalence rates.
Hot Targets, Mechanisms & Therapies
o In this section, various NASH associated targets, mechanism and upcoming
therapies are discussed. The report has 240 molecules, covers novel targets in
early research for NASH along with disease progression biomarkers associated
with NASH (Inflammatory, apoptosis, fibrosis).
Market analysis
o In market analysis section, global NASH drugs market is indicated along with the
estimated Peak sales ($) of leading clinical stage drugs forecasted from 2021-
2028.
o Forecasting model for NASH market.
o NASH market dynamics.
o NASH Market and estimated Peak sales of 6 clinical candidates (GFT505
(Genfit), OCA (Intercept), IVA 337 (Inventiva Pharma), Cenicriviroc (Allergan),
MGL 3196 (Madrigal), and GS-0976 (Firsocostat) (Gilead)).
o NASH related deals analysis with financials (upfront, milestones and royalties).
o Funding scenario in NASH market.
Pipeline Analysis
o Pipeline analysis was carried to get deeper insights on various treatment
modalities in discovery, preclinical & development section, pipelines from major
companies were identified and Potential targets were reported along with
Mechanism of action, Current development status & nature of molecule. Pipeline
analysis by developmental stage (Discovery to Clinical development).
o Pipeline analysis by modalities
Monoclonal Antibodies pipeline analysis
RNA-therapeutics pipeline analysis
Recombinant protein pipeline analysis
o Pipeline analysis by leading players & Target analysis
o Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic and
Metabolic)
Key Players Analysis
o The key player’s analysis section provides an in-depth understanding of various
companies working on Nonalcoholic steatohepatitis (NASH) and their Pipelines
with development phase as well as understanding partnering strategies such as
deals entered by the company
o Global key players overview
o Global key players Pipeline data (Discovery, Pre-clinical & Clinical development)
o Global key players: deals (Collaborations, Licensing, Service agreements, grants,
funds).
Media contact:
Mr. Satish Birudukota,
Email: bd@iq4i.com, satish.birudukota@iq4i.com,
Phone: +91 8147030229